健康元：我们正着重推进 PDE4 单靶点创新药物的研发，这款新药设计为吸入制剂，通过局部用药可规避 PDE4 抑制剂全身用药副作用较大的问题，同时能针对性抑制炎症因子释放

互动易2025-07-29

有投资者向健康元提问，看到恒瑞医药将PDE3/4抑制剂授权给GSK的消息，想请教一下，健康元在这类靶点上是否有相关布局？尤其是针对COPD等疾病的在研药物，目前有没有明确的研发进展或后续规划呢？公司回答表示，感谢您的关注。近期，默沙东以约 100 亿美元收购 Verona Pharma，将其 PDE3/4 抑制剂恩塞芬汀纳入旗下；恒瑞医药也将用于治疗 COPD 的 PDE3/4 抑制剂 HRS-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2555039426?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-29 15:36","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2555039426","market":"sh","top_or_hot":-1,"title":"健康元：我们正着重推进 PDE4 单靶点创新药物的研发，这款新药设计为吸入制剂，通过局部用药可规避 PDE4 抑制剂全身用药副作用较大的问题，同时能针对性抑制炎症因子释放","media":"互动易","content":"<div>\n<p>有投资者向健康元提问， 看到恒瑞医药将PDE3/4抑制剂授权给GSK的消息，想请教一下，健康元在这类靶点上是否有相关布局？尤其是针对COPD等疾病的在研药物，目前有没有明确的研发进展或后续规划呢？公司回答表示，感谢您的关注。近期，默沙东以约 100 亿美元收购 Verona Pharma，将其 PDE3/4 抑制剂恩塞芬汀纳入旗下；恒瑞医药也将用于治疗 COPD 的 PDE3/4 抑制剂 HRS-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729155122a4692b36&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>健康元：我们正着重推进 PDE4 单靶点创新药物的研发，这款新药设计为吸入制剂，通过局部用药可规避 PDE4 抑制剂全身用药副作用较大的问题，同时能针对性抑制炎症因子释放</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n健康元：我们正着重推进 PDE4 单靶点创新药物的研发，这款新药设计为吸入制剂，通过局部用药可规避 PDE4 抑制剂全身用药副作用较大的问题，同时能针对性抑制炎症因子释放\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-29 15:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729155122a4692b36&s=b><strong>互动易</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>有投资者向健康元提问， 看到恒瑞医药将PDE3/4抑制剂授权给GSK的消息，想请教一下，健康元在这类靶点上是否有相关布局？尤其是针对COPD等疾病的在研药物，目前有没有明确的研发进展或后续规划呢？公司回答表示，感谢您的关注。近期，默沙东以约 100 亿美元收购 Verona Pharma，将其 PDE3/4 抑制剂恩塞芬汀纳入旗下；恒瑞医药也将用于治疗 COPD 的 PDE3/4 抑制剂 HRS-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729155122a4692b36&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600380","symbol_name":"健康元","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729155122a4692b36&s=b","article_id":"2555039426","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729155122a4692b36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2555039426","pubTimestamp":1753774560,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"目前已上市的 PDE3/4 双靶点抑制剂创新药，其核心优势在于依托 PDE3 靶点发挥较强的支气管扩张作用，而在抗炎方面的效果相对有限，无法完全满足 COPD 患者对炎症控制的需求。因此，我们正着重推进 PDE4 单靶点创新药物的研发，这款新药设计为吸入制剂，通过局部用药可规避 PDE4 抑制剂全身用药副作用较大的问题，同时能针对性抑制炎症因子释放，恰好能弥补现有治疗中 “抗炎效果不足” 的短板，为患者提供更精准的炎症控制选择。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","600380":"健康元","BK0239":"医药制造","BK0077":"质押式回购","BK0188":"融资融券","BK0028":"国家队","BK0114":"健康中国","BK0046":"生物疫苗"},"translate_title":"Joincare: We are focusing on promoting the research and development of PDE4 single-target innovative drugs. This new drug is designed as an inhalation preparation. Through topical use, it can avoid the problem of large side effects of systemic use of PDE4 inhibitors, and at the same time, it can inhibit the release of inflammatory factors","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"600380":1},"content_text":"有投资者向健康元提问， 看到恒瑞医药将PDE3/4抑制剂授权给GSK的消息，想请教一下，健康元在这类靶点上是否有相关布局？尤其是针对COPD等疾病的在研药物，目前有没有明确的研发进展或后续规划呢？公司回答表示，感谢您的关注。近期，默沙东以约 100 亿美元收购 Verona Pharma，将其 PDE3/4 抑制剂恩塞芬汀纳入旗下；恒瑞医药也将用于治疗 COPD 的 PDE3/4 抑制剂 HRS-9821 许可给 GSK 。这些交易充分彰显了 COPD 赛道的巨大潜力与未满足的临床需求，也标志着吸入型PDE家族从“技术验证”到了“商业兑现”的关键阶段，备受市场关注。 COPD 作为高发的慢性呼吸疾病，患者基数庞大且呈持续增长趋势。传统制剂存在药物反应不佳，难以有效控制炎症，导致症状持续加重，反复急性发作等问题，在疗效稳定性或安全性上存在一定局限性。目前已上市的 PDE3/4 双靶点抑制剂创新药，其核心优势在于依托 PDE3 靶点发挥较强的支气管扩张作用，而在抗炎方面的效果相对有限，无法完全满足 COPD 患者对炎症控制的需求。因此，我们正着重推进 PDE4 单靶点创新药物的研发，这款新药设计为吸入制剂，通过局部用药可规避 PDE4 抑制剂全身用药副作用较大的问题，同时能针对性抑制炎症因子释放，恰好能弥补现有治疗中 “抗炎效果不足” 的短板，为患者提供更精准的炎症控制选择。 除此之外，我们还布局了PREP 抑制剂、TSLP单抗、新一代吸入性糖皮质激素等针对COPD的在研产品，这些药物将形成协同，逐步构建覆盖不同治疗需求的 COPD 解决方案。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555039426","isCrawlerRequest":true}